Cell therapy research has been growing rapidly in recent years due to its potential to treat multiple diseases. The successful release of KYMRIAH® and YESCARTA® demonstrates that cell therapy is no longer just in the realm of research but has true clinical significance, perpetuating what might be the new gold rush of cell therapy research.
While the World Health Organization (WHO) acknowledges the promising potential that cell therapy can be used to treat several conditions, they highlight the need for greater regulation to ensure safety and efficacy. Likewise, the US Food & Drug Administration (FDA) also clarifies the need for more stringent testing regarding patient safety and has issued several recommendations in this area, notably, the utilization of correct starting material for the culturing and expansion of cells, as well as demonstrating “sufficient evidence” for efficacy and safety.
Current technologies, particularly for potency and safety testing, take too long; are prone to inconsistency or are too expensive for comprehensive analysis. As such, new tools are needed to overcome these limitations.
This is where our next generation Immunoassay come in. Combining speed, consistency and sensitivity, several different immunoassays were developed to overcome those challenges. In this webinar, we will introduce the current challenges of cell therapy and how using the right tools can help you speed up your workflow.
